Hong Kong Intellectual Property Department Grants Patent For bioAffinity’s Proprietary Platform Technology For Predicting Likelihood Of Lung Cancer Using Flow Cytometry And Fluorescent Markers To Characterize Cell Populations In Sputum

Loading news article.

Hong Kong Intellectual Property Department Grants Patent For bioAffinity’s Proprietary Platform Technology For Predicting Likelihood Of Lung Cancer Using Flow Cytometry And Fluorescent Markers To Characterize Cell Populations In Sputum | WAPE

Hong Kong Intellectual Property Department Grants Patent For bioAffinity’s Proprietary Platform Technology For Predicting Likelihood Of Lung Cancer Using Flow Cytometry And Fluorescent Markers To Characterize Cell Populations In Sputum

Article summary

Related companies

Analyzed by WAPE AI.

Comments —